US drug companies pledge to keep price rises “reasonable” as legislators try to rein in costs
Leaders in the pharmaceutical and biotechnology industries have signed a commitment to pricing that enables “broad” and “uninterrupted” patient access in the face of action from US lawmakers to drive…
